“Patent Thickets” on Biologics and What Could Be Done To Chop Them Down to Size

May 10, 2022

Multiple patents on original biologics delay when biosimilars get on the market in the US. University of Denver Sturm College of Law legal experts argue in a preprint that changes in how the original patents are written could reduce the number of duplicative patents and legal gamesmanship.

Will Cyltezo Be Accepted As Interchangeabe With Humira? Researchers Sow Some Doubt.

May 10, 2022

A Cleveland Clinic researcher anticipates that the FDA’s definition of strength of formulation could impair acceptance of Boehringer Ingelheim’s biosimilar to Humira (adalimumab), even though the FDA has approved the biosimilar as “interchangeable” to Humira.

Biosimilars Made a Significant Dent on 2021 Drug Spending

May 09, 2022

Although spending on prescription drugs marched higher in 2021, the spending might have been significantly higher were it not for the savings from biosimilars, which appear to be gaining traction, according to a new report.

Humira Biosimilars Are Hitting the Market in 2023. Finally. But Will Prescriptions Follow?

April 07, 2022

Marcus Snow, MD, , chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.